$53.99+2.35% · 3M
Moving avg
1W+4.55%
1M+7.00%
3M+7.02%
6M+10.34%
YTD+0.41%
1Y-5.83%
3Y+11.50%
5Y-57.41%
52-week range
$44.1229% of range$78.48
Company health
Value1/6
Growth6/6
Profitability0/6
Health4/6
Dividend0/6
Bull vs bear
Strengths
- Analysts see 35% upside to a $73 target
- Analyst consensus is "Buy"
- Revenue compounding 30% a year
Risks
- Currently unprofitable
- Burning free cash flow
- More volatile than the market (beta 1.7)
Key statistics
Valuation
Market cap
$5.21B
Enterprise value
$5.55B
P/E ratio (TTM)
-11.02x
P/S ratio (TTM)
377.74x
EV/EBITDA
-12.23x
Per share & returns
EPS (TTM)
-$4.67
Dividend yield
0.00%
Beta (1Y)
1.70
30-day change
+7.00%
Trading
Volume (24h)
0
Previous close
$54.07
Shares outstanding
96.45M
About CRISPR Therapeutics AG
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
CRSP
CRISPR Therapeutics AG is a mid-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (Switzerland) and trade under the ticker CRSP.
Frequently asked questions
What is CRISPR Therapeutics AG's market cap?
CRISPR Therapeutics AG (CRSP) has a market capitalization of $5.21B.
What sector is CRISPR Therapeutics AG in?
CRISPR Therapeutics AG operates in the Healthcare sector, Biotechnology industry.
What exchange does CRSP trade on?
CRSP trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,220.51+0.45%
$1.15T cap
Johnson & JohnsonJNJ
$260.86+0.41%
$628.65B cap
AbbVie Inc.ABBV
$248.66-0.57%
$439.33B cap
UnitedHealth Group IncorporatedUNH
$405.59+0.85%
$368.33B cap
Roche Holding AGSWX: ROP
CHF 365.50-0.92%
$357.62B cap
Merck & Co., Inc.MRK
$132.93+1.92%
$328.31B cap
Novartis AGSWX: NOVN
CHF 124.20-1.32%
$290.17B cap
AstraZeneca PLCLON: AZN
£117.02-1.20%
$244.86B cap